Regeneron and Fujifilm Diosynth Biotechnologies Announce Groundbreaking Partnership

In a significant move to bolster the production of commercial biologic medicines in the United States, Regeneron Pharmaceuticals Inc. has entered into a monumental agreement with Fujifilm Diosynth Biotechnologies. This collaboration, centered at Fujifilm's campus in North Carolina, represents a total investment of over $3 billion, encompassing technology transfer and a decade-long commitment.

A Strategic Move to Meet Growing Demands

"Our partnership with Fujifilm is a testament to our shared commitment to excellence and innovation in biologic medicine production," stated Daniel Van Plew, Executive Vice President of Regeneron. The companies are already mobilizing to enhance production capabilities at Fujifilm’s Holly Springs facility, ensuring the highest standards are met.

Regeneron's Expanding Footprint in the US

Beyond this partnership, Regeneron is channeling more than $7 billion into expanding its production and infrastructure across New York and North Carolina, signaling a robust growth trajectory in the biopharmaceutical sector.